SUSMED, Inc.
4263.T · JPX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 1.43 | 0.09 | -0.07 | 2.06 |
| FCF Yield | 0.00% | 0.00% | 0.00% | 0.00% |
| EV / EBITDA | -87.88 | -39.03 | 31.69 | -38.44 |
| Quality | ||||
| ROIC | -3.13% | -3.47% | 3.55% | -3.38% |
| Gross Margin | 91.95% | 93.32% | 98.77% | 90.24% |
| Cash Conversion Ratio | – | – | – | – |
| Growth | ||||
| Revenue 3-Year CAGR | -3.63% | -4.49% | -3.13% | 33.53% |
| Free Cash Flow Growth | 0.00% | 0.00% | 0.00% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | 35.23 | 29.26 | -26.79 | 31.16 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 3.38 | 7.36 | 0.00 | 0.00 |
| Cash Conversion Cycle | 59.29 | 43.37 | 3.97 | 41.71 |